Skip to content
value.today

Vigeo Therapeutics, Inc.

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2011
Total raised
$10 M
2 rounds on record
Latest round
$8 M
Mar 2021
First round on record
Jun 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vigeo Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$8 MNo. 2$2 to $10 million

Vigeo Therapeutics, Inc.: Raise no. 2, Mar 2021

Investors in this round

1 investor had bought by the notice of Mar 24, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$7,580,137
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jing Watnick · Executive Officer, Director
  • Peter B. Finn · Executive Officer
  • James E. Mahoney · Director
  • Stephanie E. O'Brien · Director
  • Westerly E. Nolin, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter B Finn, Secretary. Newest notice filed Mar 24, 2021. Read the notice at the SEC.

equitySEC
Jun 2015$3 MNo. 1$2 to $10 million

Vigeo Therapeutics, Inc.: Raise no. 1, Jun 2015

Investors in this round

1 investor had bought by the notice of Jun 12, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $10 M offered; $8 M still to sell
Smallest investment taken
$2,500,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,875,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Peter B Finn · Executive Officer, Director
  • Jason Dinges · Director
  • Stephanie O'Brien · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive salaries”

Signed by Peter B. Finn, Director. Newest notice filed Jun 12, 2015. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vigeo Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2021

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vigeo Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vigeo Therapeutics, Inc.
NameRoleNamed in
Jing WatnickExecutive officerMar 2021
Peter B. FinnExecutive officerMar 2021
Peter B FinnExecutive officerJun 2015
James E. MahoneyDirectorMar 2021
Jing WatnickDirectorMar 2021
Stephanie E. O'BrienDirectorMar 2021
Westerly E. Nolin, Ph.D.DirectorMar 2021
Jason DingesDirectorJun 2015
Peter B FinnDirectorJun 2015
Stephanie O'BrienDirectorJun 2015